A method for preparing a composite material, including the following steps: providing metal oxide nanoparticles and a polyaromatic compound having a structure represented by Formula I,

##STR00001##

where, Ar.sub.1, Ar.sub.2, Ar.sub.3, and Ar.sub.4 are selected from aromatic rings; X.sub.1, X.sub.2, and X.sub.3 are selected from active groups configured for binding with the metal oxide nanoparticles, each of R.sub.1, R.sub.2, and R.sub.3 independently contains at least one of alkylene, amine, —N═N—, alkenyl, alkynyl, and phenyl, and each of m, n, and y is independently selected from 0 or positive integers; dispersing the polyaromatic compound and the metal oxide nanoparticles in a solvent to yield a mixed solution; and heating the mixed solution to yield the composite material. A composite material includes: a polyaromatic compound and metal oxide nanoparticles. The polyaromatic compound is connected to the metal oxide nanoparticles. The polyaromatic compound has a structure represented by Formula I.

A salt represented by formula (I), a quencher, and a resist composition including the same: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represent a halogen atom, an alkyl fluoride group having 1 to 6 carbon atoms or a hydrocarbon group having 1 to 18 carbon atoms, —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; and m1, m2, m3 and m4 represent an integer of 0 to 4. When m1 is 2 or more, a plurality of R.sup.1 may be the same or different from each other. When m2 is 2 or more, a plurality of R.sup.2 may be the same or different from each other. When m3 is 2 or more, a plurality of R.sup.3 may be the same or different from each other. When m4 is 2 or more, a plurality of R.sup.4 may be the same or different from each other.

A salt represented by formula (I), a quencher, and a resist composition including the same: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represent a halogen atom, an alkyl fluoride group having 1 to 6 carbon atoms or a hydrocarbon group having 1 to 18 carbon atoms, —CH.sub.2— included in the hydrocarbon group may be replaced by —O— or —CO—; and m1, m2, m3 and m4 represent an integer of 0 to 4. When m1 is 2 or more, a plurality of R.sup.1 may be the same or different from each other. When m2 is 2 or more, a plurality of R.sup.2 may be the same or different from each other. When m3 is 2 or more, a plurality of R.sup.3 may be the same or different from each other. When m4 is 2 or more, a plurality of R.sup.4 may be the same or different from each other.

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

A process for the synthesis of Dapsone and intermediates thereof are described.

A process for the synthesis of Dapsone and intermediates thereof are described.

The present disclosure provides an organic compound that has a mother skeleton with a fused-ring structure, an electron-withdrawing group bonded to the mother skeleton, and an electron-donating group bonded to the mother skeleton, wherein the electron-withdrawing group is bonded at a position satisfying the following relationship in the mother skeleton.

Σ|C.sub.H|>Σ|C.sub.L|  (1)

(C.sub.H: 2PZ atomic orbital coefficient of a carbon at a substitution site in the HOMO of the mother skeleton)

(C.sub.L: 2PZ atomic orbital coefficient of the carbon at the substitution site in the LUMO of the mother skeleton)

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: ##STR00001##
The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: ##STR00001##
The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.